Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to Acino for ~$200M in NEMEA Countries

 Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to Acino for ~$200M in NEMEA Countries

Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to Acino for ~$200M in NEMEA Countries

Shots:

  • Takeda to receive ~$200M for divesting its 30 select prescription pharmaceutical and OTC products traded in Near East, Middle East and Africa (NEMEA) countries. Acino to get rights, title, and interest to the products in the portfolio exclusive in NEMEA. The transaction is expected to close in Q4’19
  • Additionally, Takeda and Acino will sign multi-year manufacturing and supply agreement under which Takeda will continue to manufacture the products on behalf of Acino
  • The collaboration will optimize Takeda’s portfolio in the NEMEA region, reduces its debt and accelerates deleveraging towards reaching its target of 2.0x net debt/adjusted EBITDA in the next 3-5yrs.

Click here to­ read full press release/ article | Ref: Takeda| Image: Fortune

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post